Jeff Kuret

Jeff Kuret

Auto-generated profile, based on publicly available information

Jeff Kuret

The Ohio State University College of Medicine

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2014 in Biochemical Journal
Verified
Journal Article
Closed access
PDF file
KFKristen Funk
Kristen Funk
STStefani Thomas
Stefani Thomas
KSKelsey N. Schafer
Kelsey N. Schafer
GCGrace L. Cooper
Grace L. Cooper
ZLZhongping Liao
Zhongping Liao
JKJeff Kuret
Jeff Kuret
In Alzheimer's disease, the microtubule-associated protein tau dissociates from the neuronal cytoskeleton and aggregates to form cytoplasmic inclusions. Although hyperphosphorylation of tau serine and threonine residues is an established trigger of tau misfunction and aggregation, tau modifications extend to lysine residues as well, raising the possibility that different modification signatures depress or promote aggregation propensity depending on site occupancy. To identify lysine residue modifications associated with normal tau function, soluble tau proteins isolated from four cognitively normal human brains were characterized by MS methods. The major detectable lysine modification was found to be methylation, which appeared in the form of mono- and di-methyl lysine residues distributed among at least 11 sites. Unlike tau phosphorylation sites, the frequency of lysine methylation was highest in the microtubule-binding repeat region that mediates both microtubule binding and homotypic interactions. When purified recombinant human tau was modified in vitro through reductive methylation, its ability to promote tubulin polymerization was retained, whereas its aggregation propensity was greatly attenuated at both nucleation and extension steps. These data establish lysine methylation as part of the normal tau post-translational modification signature in human brain, and suggest that it can function in part to protect against pathological tau aggregation.

28 October 2011 in Acta Neuropathologica
Verified
Journal Article
Open access
PDF file
STStefani Thomas
Stefani Thomas
KFKristen Funk
Kristen Funk
YWYunhu Wan
Yunhu Wan
ZLZhongping Liao
Zhongping Liao
PDPeter Davies
Peter Davies
AYAustin J. Yang
Austin J. Yang
In sporadic Alzheimer’s disease (AD), neurofibrillary lesion formation is preceded by extensive post-translational modification of the microtubule associated protein tau. To identify the modification signature associated with tau lesion formation at single amino acid resolution, immunopurified paired helical filaments were isolated from AD brain and subjected to nanoflow liquid chromatography–tandem mass spectrometry analysis. The resulting spectra identified monomethylation of lysine residues as a new tau modification. The methyl-lysine was distributed among seven residues located in the projection and microtubule binding repeat regions of tau protein, with one site, K254, being a substrate for a competing lysine modification, ubiquitylation. To characterize methyl lysine content in intact tissue, hippocampal sections prepared from post mortem late-stage AD cases were subjected to double-label confocal fluorescence microscopy using anti-tau and anti-methyl lysine antibodies. Anti-methyl lysine immunoreactivity colocalized with 78 ± 13% of neurofibrillary tangles in these specimens. Together these data provide the first evidence that tau in neurofibrillary lesions is post-translationally modified by lysine methylation.

1 June 2012 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
QZQi Zhong
Qi Zhong
ECErin E. Congdon
Erin E. Congdon
HNHaikady N. Nagaraja
Haikady N. Nagaraja
JKJeff Kuret
Jeff Kuret
The risk of developing tauopathic neurodegenerative disease depends in part on the levels and composition of six naturally occurring Tau isoforms in human brain. These proteins, which form filamentous aggregates in disease, vary only by the presence or absence of three inserts encoded by alternatively spliced exons 2, 3, and 10 of the Tau gene (MAPT). To determine the contribution of alternatively spliced segments to Tau aggregation propensity, the aggregation kinetics of six unmodified, recombinant human Tau isoforms were examined in vitro using electron microscopy assay methods. Aggregation propensity was then compared at the level of elementary rate constants for nucleation and extension phases. We found that all three alternatively spliced segments modulated Tau aggregation but through differing kinetic mechanisms that could synergize or compete depending on sequence context. Overall, segments encoded by exons 2 and 10 promoted aggregation, whereas the segment encoded by exon 3 depressed it with its efficacy dependent on the presence or absence of a fourth microtubule binding repeat. In general, aggregation propensity correlated with genetic risk reported for multiple tauopathies, implicating aggregation as one candidate mechanism rationalizing the correlation between Tau expression patterns and disease.

1 May 2008 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
ECErin E. Congdon
Erin E. Congdon
SKSohee Kim
Sohee Kim
JBJonathan Bonchak
Jonathan Bonchak
TSTanakorn Songrug
Tanakorn Songrug
AMAnastasios Matzavinos
Anastasios Matzavinos
JKJeff Kuret
Jeff Kuret
Filamentous inclusions composed of the microtubule-associated protein tau are found in Alzheimer disease and other tauopathic neurodegenerative diseases, but the mechanisms underlying their formation from full-length protein monomer under physiological conditions are unclear. To address this issue, the fibrillization of recombinant full-length four-repeat human tau was examined in vitro as a function of time and submicromolar tau concentrations using electron microscopy assay methods and a small-molecule inducer of aggregation, thiazine red. Data were then fit to a simple homogeneous nucleation model with rate constant constraints established from filament dissociation rate, critical concentration, and mass-per-unit length measurements. The model was then tested by comparing the predicted time-dependent evolution of length distributions to experimental data. Results indicated that once assembly-competent conformations were attained, the rate-limiting step in the fibrillization pathway was tau dimer formation. Filament elongation then proceeded by addition of tau monomers to nascent filament ends. Filaments isolated at reaction plateau contained ∼2 tau protomers/β-strand spacing on the basis of mass-per-unit length measurements. The model suggests four key steps in the aggregation pathway that must be surmounted for tau filaments to form in disease.

1 January 2005 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
JKJeff Kuret
Jeff Kuret
CCCarmen N. Chirita
Carmen N. Chirita
ECErin E. Congdon
Erin E. Congdon
TKTheresa Kannanayakal
Theresa Kannanayakal
GLGuibin Li
Guibin Li
QZQi Zhong
Qi Zhong

14 October 2010 in Neuropathology and Applied Neurobiology
Verified
Journal Article
Closed access
PDF file
KFKristen Funk
Kristen Funk
RMR. E. Mrak
R. E. Mrak
JKJ. Kuret
J. Kuret